The available scientific data suggest that the contribution of adjuvant chemotherapy to reducing the risk of death of resected EGFR-mutated NSCLC patients is really limited, and the treatment is associated with a non-negligible risk of severe adverse events. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.